127 related articles for article (PubMed ID: 38142040)
41. [Application of carbon nanoparticles suspension injection in uremic patients with secondary hyperparathyroidism underwent total parathyroidectomy: 2 case report and literature review].
Liu Q; Gan Y; Wu J; Li X; Fossi Paul Cedric N
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 42(7):865-868. PubMed ID: 28845015
[TBL] [Abstract][Full Text] [Related]
42. [Re-operation treatment in uremic patients complicated with persistent secondary hyperparathyroidism after parathyroidectomy with autotransplantation].
Bo SJ; Xu XF; Qiu CY; Wang TT; Ning YD; Li HY
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Jan; 32(2):142-147. PubMed ID: 29757564
[No Abstract] [Full Text] [Related]
43. Functioning oxyphil cell adenomas of parathyroid gland: immunoperoxidase evidence of hormonal activity in oxyphil cells.
Ordonez NG; Ibanez ML; Mackay B; Samaan NA; Hickey RC
Am J Clin Pathol; 1982 Nov; 78(5):681-9. PubMed ID: 6753566
[TBL] [Abstract][Full Text] [Related]
44. Technetium Tc 99m sestamibi sensitivity in oxyphil cell-dominant parathyroid adenomas.
Bleier BS; LiVolsi VA; Chalian AA; Gimotty PA; Botbyl JD; Weber RS
Arch Otolaryngol Head Neck Surg; 2006 Jul; 132(7):779-82. PubMed ID: 16847189
[TBL] [Abstract][Full Text] [Related]
45. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
46. Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism.
Yamaguchi S; Yachiku S; Morikawa M
J Clin Endocrinol Metab; 1997 Aug; 82(8):2681-8. PubMed ID: 9253354
[TBL] [Abstract][Full Text] [Related]
47. [Ultrastructural localization of aluminum in the parathyroid cells of patients on chronic dialysis].
Galle P; Campos H; Giudicelli C
C R Seances Acad Sci III; 1983; 296(12):545-50. PubMed ID: 6409363
[TBL] [Abstract][Full Text] [Related]
48. Functioning oxyphil cell adenomas of the parathyroid gland. A study of 15 cases.
Wolpert HR; Vickery AL; Wang CA
Am J Surg Pathol; 1989 Jun; 13(6):500-4. PubMed ID: 2729500
[TBL] [Abstract][Full Text] [Related]
49. Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation.
Lewin E; Garfia B; Recio FL; Rodriguez M; Olgaard K
J Am Soc Nephrol; 2002 Aug; 13(8):2110-6. PubMed ID: 12138143
[TBL] [Abstract][Full Text] [Related]
50. [The parathyroid gland under normal and experimental conditions].
Shoumura S; Emura S; Isono H
Kaibogaku Zasshi; 1993 Feb; 68(1):5-29. PubMed ID: 8517114
[TBL] [Abstract][Full Text] [Related]
51. Increased parathyroid expression of klotho in uremic rats.
Hofman-Bang J; Martuseviciene G; Santini MA; Olgaard K; Lewin E
Kidney Int; 2010 Dec; 78(11):1119-27. PubMed ID: 20631679
[TBL] [Abstract][Full Text] [Related]
52. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism.
Carling T; Rastad J; Szabó E; Westin G; Akerström G
J Clin Endocrinol Metab; 2000 May; 85(5):2000-3. PubMed ID: 10843188
[TBL] [Abstract][Full Text] [Related]
53. Alteration in density, morphology and parathyroid hormone release of dispersed parathyroid cells from patients with hyperparathyroidism.
Rudberg C; Grimelius L; Johansson H; Ljunghall S; Odselius R; Pertoft H; Rastad J; Wide L; Akerström G
Acta Pathol Microbiol Immunol Scand A; 1986 Jul; 94(4):253-61. PubMed ID: 3751571
[TBL] [Abstract][Full Text] [Related]
54. Parathyroid gland adenoma in primary hyperparathyroidism: report of two cases--chief and oxyphil cell adenoma.
Yoshihara T; Morita M; Masuda T; Kanda T; Takemiya S
Auris Nasus Larynx; 1991; 18(2):189-97. PubMed ID: 1741713
[TBL] [Abstract][Full Text] [Related]
55. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients.
Komaba H; Goto S; Fujii H; Hamada Y; Kobayashi A; Shibuya K; Tominaga Y; Otsuki N; Nibu K; Nakagawa K; Tsugawa N; Okano T; Kitazawa R; Fukagawa M; Kita T
Kidney Int; 2010 Feb; 77(3):232-8. PubMed ID: 19890272
[TBL] [Abstract][Full Text] [Related]
56. Oxyphil cell adenoma and hyperparathyroidism.
Poole GV; Albertson DA; Marshall RB; Myers RT
Surgery; 1982 Nov; 92(5):799-805. PubMed ID: 6753205
[TBL] [Abstract][Full Text] [Related]
57. Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas.
Costa-Guda J; Tokura T; Roth SI; Arnold A
BMC Endocr Disord; 2007 Oct; 7():8. PubMed ID: 17916247
[TBL] [Abstract][Full Text] [Related]
58. Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients.
Wang X; Sun B; Zhou F; Hu J; Yu X; Peng T
Chin Med J (Engl); 2001 Apr; 114(4):410-4. PubMed ID: 11780466
[TBL] [Abstract][Full Text] [Related]
59. Occurrence of oxyphil cells in suppressed parathyroid glands.
Boquist L
Cell Tissue Res; 1975 Nov; 163(4):465-70. PubMed ID: 1201588
[TBL] [Abstract][Full Text] [Related]
60. Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis.
Martin LN; Kayath MJ; Vieira JG; Nosé-Alberti V
Histopathology; 1998 Jul; 33(1):46-51. PubMed ID: 9726048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
